Mesothelin-targeted Immunotherapies for Malignant Pleural Mesothelioma

Overview

Journal Ann Cardiothorac Surg

Publisher AME Publishing Company

Date 2013 Aug 27

PMID 23977538

Citations 10

Authors

Jonathan Villena-Vargas

Prasad S Adusumilli

Affiliations

Soon will be listed here.

Citing Articles

Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.

Santin A, Vergote I, Gonzalez-Martin A, Moore K, Oaknin A, Romero I Int J Gynecol Cancer. 2022; 33(4):562-570.

PMID: 36564099 PMC: 10086500. DOI: 10.1136/ijgc-2022-003927.

Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.

Kandra P, Nandigama R, Eul B, Huber M, Kobold S, Seeger W Front Immunol. 2022; 13:903562.

PMID: 35720364 PMC: 9201083. DOI: 10.3389/fimmu.2022.903562.

The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.

Zhang J, Wang L Technol Cancer Res Treat. 2019; 18:1533033819831068.

PMID: 30798772 PMC: 6391541. DOI: 10.1177/1533033819831068.

Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.

White M, Freistaedter A, Jones G, Zervos E, Roper R PLoS One. 2018; 13(2):e0193131.

PMID: 29474384 PMC: 5825036. DOI: 10.1371/journal.pone.0193131.

Improving theranostics in pancreatic cancer.

King J, Bouvet M, Singh G, Williams J J Surg Oncol. 2017; 116(1):104-113.

PMID: 28513912 PMC: 5520663. DOI: 10.1002/jso.24625.

References

Brockstedt D, Giedlin M, Leong M, Bahjat K, Gao Y, Luckett W . Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A. 2004; 101(38):13832-7. PMC: 518841. DOI: 10.1073/pnas.0406035101. View

Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W . Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol. 2010; 28(20):3316-22. DOI: 10.1200/JCO.2009.26.9944. View

Flores R, Krug L, Rosenzweig K, Venkatraman E, Vincent A, Heelan R . Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2007; 1(4):289-95. View

Tchou J, Wang L, Selven B, Zhang H, Conejo-Garcia J, Borghaei H . Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat. 2012; 133(2):799-804. PMC: 4964602. DOI: 10.1007/s10549-012-2018-4. View

Hassan R, Bullock S, Premkumar A, Kreitman R, Kindler H, Willingham M . Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007; 13(17):5144-9. DOI: 10.1158/1078-0432.CCR-07-0869. View

Pegram H, Lee J, Hayman E, Imperato G, Tedder T, Sadelain M . Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012; 119(18):4133-41. PMC: 3359735. DOI: 10.1182/blood-2011-12-400044. View

Le D, Brockstedt D, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J . A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2011; 18(3):858-68. PMC: 3289408. DOI: 10.1158/1078-0432.CCR-11-2121. View

Hassan R, Cohen S, Phillips M, Pastan I, Sharon E, Kelly R . Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010; 16(24):6132-8. PMC: 3057907. DOI: 10.1158/1078-0432.CCR-10-2275. View

Di Stasi A, Tey S, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C . Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011; 365(18):1673-83. PMC: 3236370. DOI: 10.1056/NEJMoa1106152. View

10.

Robinson B, Creaney J, Lake R, Nowak A, William Musk A, de Klerk N . Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003; 362(9396):1612-6. DOI: 10.1016/S0140-6736(03)14794-0. View

11.

Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher W . Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 2008; 7(2):286-96. PMC: 2929838. DOI: 10.1158/1535-7163.MCT-07-0483. View

12.

Zhang Y, Xiang L, Hassan R, Pastan I . Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A. 2007; 104(43):17099-104. PMC: 2040446. DOI: 10.1073/pnas.0708101104. View

13.

Suzuki K, Kadota K, Sima C, Sadelain M, Rusch V, Travis W . Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother. 2011; 60(12):1721-8. PMC: 6250069. DOI: 10.1007/s00262-011-1073-8. View

14.

Servais E, Colovos C, Rodriguez L, Bograd A, Nitadori J, Sima C . Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res. 2012; 18(9):2478-89. PMC: 3759995. DOI: 10.1158/1078-0432.CCR-11-2614. View

15.

Sadelain M, Riviere I, Brentjens R . Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003; 3(1):35-45. DOI: 10.1038/nrc971. View

16.

Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L . HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997; 276(5319):1719-24. DOI: 10.1126/science.276.5319.1719. View

17.

Servais E, Suzuki K, Colovos C, Rodriguez L, Sima C, Fleisher M . An in vivo platform for tumor biomarker assessment. PLoS One. 2011; 6(10):e26722. PMC: 3202552. DOI: 10.1371/journal.pone.0026722. View

18.

Chowdhury P, Viner J, Beers R, Pastan I . Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A. 1998; 95(2):669-74. PMC: 18478. DOI: 10.1073/pnas.95.2.669. View

19.

Kelly R, Sharon E, Pastan I, Hassan R . Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther. 2012; 11(3):517-25. PMC: 3297681. DOI: 10.1158/1535-7163.MCT-11-0454. View

20.

Sadelain M, Brentjens R, Riviere I . The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009; 21(2):215-23. PMC: 5548385. DOI: 10.1016/j.coi.2009.02.009. View